Dr. Reddy’s Lab is currently trading at Rs. 2536.00, up by 27.35 points or 1.02% from its previous closing of Rs. 2510.50 on the BSE.
The scrip opened at Rs. 2536.90 and has touched a high and low of Rs. 2548.00 and Rs. 2519.55 respectively. So far 10847 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2965.20 on 02-May-2019 and a 52 week low of Rs. 2065.30 on 15-Feb-2019.
Last one week high and low of the scrip stood at Rs. 2567.50 and Rs. 2352.00 respectively. The current market cap of the company is Rs. 42043.41 crore.
The promoters holding in the company stood at 26.76%, while Institutions and Non-Institutions held 44.50% and 14.44% respectively.
Dr. Reddy’s Laboratories has launched Vigabatrin Powder for Oral Solution, USP in 500 mg per packet, a therapeutic equivalent generic version of Sabril (vigabatrin) Powder for Oral Solution, USP, approved by the U.S. Food and Drug Administration (USFDA). Dr. Reddy's Vigabatrin Powder for Oral Solution, USP is available in 500 mg per packet in count size of 50 per carton.
The Sabril brand and generic had U.S. sales of approximately $274 million MAT for the most recent twelve months ending in June 2019 according to IMS Health.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.